Skip to main content

Prevention

10-24-2023 | Type 2 diabetes | News

Prediabetes remission with lifestyle intervention reduces type 2 diabetes risk

A post-hoc analysis of the German Prediabetes Lifestyle Intervention Study has found that people who achieve remission of prediabetes by losing weight through lifestyle intervention for 12 months may reduce their risk for developing type 2 diabetes.

03-21-2023 | Diabetes prevention | News

Verapamil promising for preserving beta-cell function in children

Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.

11-18-2022 | Teplizumab | News

FDA clearance for teplizumab to slow type 1 diabetes onset

Click through to read more on this announcement

05-30-2022 | Prediabetes | News

Vitamin D fails to prevent type 2 diabetes among adults with impaired glucose tolerance

Daily treatment with the vitamin D analog eldecalcitol has not prevented the development of type 2 diabetes or promoted a return to normoglycemia in a study of Japanese adults with impaired glucose tolerance.

12-02-2021 | Dapagliflozin | News

Pooled analysis supports diabetes prevention effect of dapagliflozin

A pooled analysis of the DAPA-HF and DAPA-CKD trials suggests that taking the SGLT2 inhibitor dapagliflozin reduced the participants’ risk for developing type 2 diabetes by around a third.

Person having blood pressure checked

11-17-2021 | Diabetes prevention | News

Lowering blood pressure may help type 2 diabetes prevention

Reducing blood pressure may be an effective strategy for the prevention of new-onset type 2 diabetes, suggest researchers from the Blood Pressure Lowering Treatment Trialists’ Collaboration.

09-03-2021 | Prediabetes | News

Raising HbA1c prediabetes threshold could direct care to highest risk individuals

UK researchers suggest raising the glycated hemoglobin threshold that is used to identify individuals at high risk for developing type 2 diabetes within 5 years.

07-07-2021 | Immunotherapy | News

Imatinib could slow beta-cell decline in early type 1 diabetes ​

A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell function in people with newly diagnosed type 1 diabetes, but the effect is not sustained in the longer term, phase 2 study findings indicate.